Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimization in heart failure with reduced ejection fraction: The REALIZE-K open-label run-in phase

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111927" target="_blank" >RIV/00843989:_____/25:E0111927 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/25:A2603DOR

Result on the web

<a href="https://doi.org/10.1002/ejhf.3787" target="_blank" >https://doi.org/10.1002/ejhf.3787</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/ejhf.3787" target="_blank" >10.1002/ejhf.3787</a>

Result language

angličtina

Original language name

Sodium zirconium cyclosilicate, hyperkalaemia, and spironolactone optimization in heart failure with reduced ejection fraction: The REALIZE-K open-label run-in phase

Original language description

In heart failure with reduced ejection fraction (HFrEF), mineralocorticoid receptor antagonists (MRAs) reduce mortality and HF hospitalizations, and are one of the key cornerstones of guideline-directed medical therapy. Hyperkalaemia (or fear of hyperkalaemia) is a major reason for their underuse. In the randomized-withdrawal phase of the REALIZE-K trial, of patients with HFrEF and prevalent hyperkalaemia or at risk of hyperkalaemia, continued use of the potassium (K+) binder sodium zirconium cyclosilicate (SZC) led to large increases in the number of participants on optimal-dose spironolactone with normokalaemia, and reduced the risk of hyperkalaemia and down-titration/discontinuation of spironolactone compared with withdrawal to placebo. Prior to the placebo-controlled, randomized-withdrawal phase of REALIZE-K, there was a run-in phase in which SZC was used to manage hyperkalaemia and spironolactone dose was optimized. This analysis evaluated the efficacy of SZC in lowering serum (s)K+ and enabling SZC titration during the run-in phase among those with prevalent hyperkalaemia on no or low-dose (12.5 mg) spironolactone; and in those identified as at high risk of hyperkalaemia on no or low-dose spironolactone, to evaluate the incidence of hyperkalaemia during spironolactone dose titration during the run-in phase and use of SZC to lower sK+ and enable maintenance of spironolactone.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30201 - Cardiac and Cardiovascular systems

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

European journal of heart failure

ISSN

1388-9842

e-ISSN

1879-0844

Volume of the periodical

27

Issue of the periodical within the volume

8

Country of publishing house

GB - UNITED KINGDOM

Number of pages

5

Pages from-to

1491-1495

UT code for WoS article

001554516500001

EID of the result in the Scopus database

2-s2.0-105013796832